• Citer

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

par Carey, Lisa L.A.;Loirat, Delphine;Punie, Kevin;Bardia, Aditya;Diéras, Veronique;Dalenc, Florence;Diamond, Jennifer J.R.;Fontaine, Christel;Wang, Grace;Rugo, Hope H.S.;Hurvitz, Sara;Kalinsky, Kevin;O'Shaughnessy, Joyce;Loibl, Sibylle;Gianni, Luca;Piccart-Gebhart, Martine ;Zhu, Yanni;Delaney, Rosemary;Phan, See;Cortes, Javier
Référence NPJ breast cancer, 8, 1, 72
Publication Publié, 2022-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician’s choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22–0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28–0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.